Advanced search

Report side effect

Report a suspected side effect or falsified product to the MHRA Yellow Card scheme.
Go to {yellow_card_logo} site
{arrow_up} Back to top

Cyclizine 50mg Tablets / Valoid 50 mg Tablets

Active Ingredient:
cyclizine hydrochloride
ADVANZ Pharma See contact details
About Medicine
{healthcare_pro_orange} This information is for use by healthcare professionals
Last updated on emc: 16 Feb 2024
1. Name of the medicinal product

Valoid 50 mg Tablets

Cyclizine Hydrochloride 50 mg Tablets

2. Qualitative and quantitative composition

Each tablet contains 50 mg of cyclizine hydrochloride.

Excipient with known effect:

Lactose (60mg/tablet).

For the full list of excipients, see section 6.1.

3. Pharmaceutical form

White, biconvex, uncoated tablet, scored; coded T4A.

The score line is to facilitate breaking for ease of swallowing and divide into equal doses.

4. Clinical particulars
4.1 Therapeutic indications

Cyclizine Hydrochloride is indicated in adults and in children aged 6 years and over for the prevention and treatment of nausea and vomiting including:-

• Motion sickness.

• Nausea and vomiting caused by narcotic analgesics and by general anaesthetics in the post-operative period.

• Vomiting associated with radiotherapy, especially for breast cancer since cyclizine does not elevate prolactin levels.

Cyclizine Hydrochloride may be of value in relieving vomiting and attacks of vertigo associated with Meniè re's disease and other forms of vestibular disturbance.

4.2 Posology and method of administration


To prevent motion sickness Cyclizine Hydrochloride should be taken about one to two hours before departure.


There have been no specific studies of Cyclizine Hydrochloride in the elderly. Experience has indicated that normal adult dosage is appropriate.

Paediatric population

Children less than 6 years of age:

Cyclizine Hydrochloride tablets are not recommended for children less than 6 years of age.

Children 6 to 12 years of age:

25 mg orally, which may be repeated up to three times a day.

Children over 12 years of age:

50 mg orally, which may be repeated up to three times a day.


50 mg orally, which may be repeated up to three times a day.

Method of administration:


4.3 Contraindications

Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.

Cyclizine is contraindicated in the presence of acute alcohol intoxication. The anti-emetic properties of cyclizine may increase the toxicity of alcohol.

4.4 Special warnings and precautions for use

As with other anticholinergic agents, Cyclizine Hydrochloride may precipitate incipient glaucoma and it should be used with caution and appropriate monitoring in patients with glaucoma, urinary retention, obstructive disease of the gastrointestinal tract, hepatic disease, phaeochromocytoma, hypertension, epilepsy and in males with possible prostatic hypertrophy.

Cyclizine should be used with caution in patients with severe heart failure or acute myocardial infarction. In such patients, cyclizine may cause a fall in cardiac output associated with increases in heart rate, mean arterial pressure and pulmonary wedge pressure.

Cyclizine should be avoided in porphyria.

There have been reports of abuse of cyclizine, either oral or intravenous, for its euphoric or hallucinatory effects. The concomitant misuse of Cyclizine Hydrochloride with large amounts of alcohol is particularly dangerous, since the antiemetic effect of cyclizine may increase the toxicity of alcohol (see also sections 4.3 and 4.5).

Cyclizine Hydrochloride contains lactose

Patients with rare hereditary problems of galactose intolerance, the Lapp lactase deficiency or glucose-galactose malabsorption should not take this medicine.

4.5 Interaction with other medicinal products and other forms of interaction

Cyclizine Hydrochloride may have additive effects with alcohol and other central nervous system depressants e.g. hypnotics, tranquillisers, anaesthetics antipsychotics, barbiturates.

Cyclizine Hydrochloride enhances the soporific effect of pethidine.

Cyclizine Hydrochloride may counteract the haemodynamic benefits of opioid analgesics.

Because of its anticholinergic activity cyclizine may enhance the side-effects of other anticholinergic drugs, and have an additive antimuscarinic action with other antimuscarinic drugs, such as atropine and some antidepressants (both tricyclics and MAOIs).

Cyclizine Hydrochloride may mask the warning signs of damage caused by ototoxic drugs such as aminoglycoside antibacterials.

4.6 Fertility, pregnancy and lactation


In the absence of any definitive human data, the use of Cyclizine Hydrochloride in pregnancy is not advised.


Cyclizine is excreted in human milk; however, the amount has not been quantified


In a study involving prolonged administration of cyclizine to male and female rats, there was no evidence of impaired fertility after continuous treatment for 90-100 days at dose levels of approximately 15 and 25 mg/kg/day. There is no experience of the effect of Cyclizine Hydrochloride on human fertility.

4.7 Effects on ability to drive and use machines

Studies designed to detect drowsiness did not reveal sedation in healthy adults who took a single oral therapeutic dose (50 mg) of cyclizine.

Patients should not drive or operate machinery until they have determined their own response.

Although there are no data available, patients should be cautioned that Cyclizine Hydrochloride may have additive effects with alcohol and other central nervous system depressants, e.g. hypnotics and tranquillisers.

4.8 Undesirable effects

Adverse reactions are ranked under heading of frequency, the most frequent first, using the following convention: Very common: (≥ 1/10); Common (≥ 1/100 to <1/10); Uncommon (≥ 1/1,000 to <1/100); Rare (≥ 1/10,000 to <1/1,000); Very rare (<1/10,000); Not known: cannot be estimated from the available data.

System Organ Class


Adverse reactions

Blood and lymphatic system disorders

Not known

Agranulocytosis, leucopenia, haemolytic anaemia, thrombocytopenia

Cardiac disorders

Not known

Tachycardia, palpitations, arrhythmias

Ear and labyrinth disorder

Not known


Eye disorders

Not known

Blurred vision, oculogyric crisis

Gastrointestinal disorders

Not known

Dryness of the mouth, nose and throat, constipation increased gastric reflux.

Nausea, vomiting, diarrhoea stomach pain

Loss of appetite

General disorders and administration site conditions

Not known


Hepatobiliary disorders

Not known

Hepatic dysfunction, hypersensitivity hepatitis, cholestatic jaundice and cholestatic hepatitis have occurred in association with cyclizine

Immune system disorders

Not known

Hypersensitivity reactions, including anaphylaxis have occurred

Musculoskeletal and connective tissue disorders

Not known

Twitching, muscle spasms

Nervous system disorders

Not known

Effects on the central nervous system have been reported with cyclizine these include somnolence, drowsiness, incoordination headache, dystonia, dyskinesia, extrapyramidal motor disturbances, restless leg syndrome, tremor, convulsions, dizziness, decreased consciousness, transient speech disorders, paraesthesia and generalised chorea

Psychiatric disorders

Not known

Disorientation, restlessness, nervousness, euphoria, insomnia and auditory and visual hallucinations have been reported, particularly when dosage recommendations have been exceeded

Renal and urinary disorders

Not known

Urinary retention

Respiratory, thoracic and mediastinal disorders

Not known

Bronchospasm, apnoea

Skin and subcutaneous tissue disorders

Not known

Urticaria, drug rash, angioedema, allergic skin reactions, fixed drug eruption photosensitivity

Vascular disorders

Not known

Hypertension, hypotension

Reporting of suspected adverse reactions

Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the Yellow Card Scheme, website: or search for MHRA Yellow Card in the Google Play or Apple App Store.

4.9 Overdose


Symptoms of acute toxicity from cyclizine arise from peripheral anticholinergic effects and effects on the central nervous system.

Peripheral anticholinergic symptoms include dry mouth, nose and throat, blurred vision, tachycardia and urinary retention. Central nervous system effects include drowsiness, dizziness, incoordination, ataxia, weakness, hyperexcitability, disorientation, impaired judgement, hallucinations, hyperkinesia, extrapyramidal motor disturbances, convulsions, hyperpyrexia and respiratory depression.

An oral dose of 5 mg/kg is likely to be associated with at least one of the clinical symptoms stated above. Younger children are more susceptible to convulsions. The incidence of convulsions, in children less than 5 years, is about 60% when the oral dose ingested exceeds 40 mg/kg.


In the management of acute overdosage with Cyclizine Hydrochloride, gastric lavage and supportive measures for respiration and circulation should be performed if necessary. Convulsions should be controlled in the usual way with parenteral anticonvulsant therapy.

5. Pharmacological properties
5.1 Pharmacodynamic properties

ATC Code: R06AE03

Pharmacotherapeutic Group: Piperazine derivatives

Mechanism of action:

Cyclizine is a histamine H1 receptor antagonist of the piperazine class which is characterised by a low incidence of drowsiness. It possesses anticholinergic and antiemetic properties. The exact mechanism by which cyclizine can prevent or suppress both nausea and vomiting from various causes is unknown. Cyclizine increases lower oesophageal sphincter tone and reduces the sensitivity of the labyrinthine apparatus. It may inhibit the part of the midbrain known collectively as the emetic centre.

Pharmacodynamic effects:

Cyclizine produces its antiemetic effect within two hours and lasts approximately four hours.

5.2 Pharmacokinetic properties


H1-blockers are well absorbed from the GI tract. Following oral administration effects develop within 30 minutes, are maximal within 1-2 hours and last, for cyclizine, for 4-6 hours.


In healthy adult volunteers the administration of a single oral dose of 50 mg cyclizine resulted in a peak plasma concentration of approximately 70 ng/mL occurring at about two hours after drug administration. The plasma elimination half-life was approximately 20 hours.


The N-demethylated derivative, norcyclizine, has been identified as a metabolite of cyclizine. Norcyclizine has little antihistaminic (H1) activity compared to cyclizine. It is widely distributed throughout the tissues and has a plasma elimination half-life of approximately 20 hours.


After a single dose of 50 mg cyclizine given to a single adult male volunteer, urine collected over the following 24 hours contained less than 1% of the total dose administered.

5.3 Preclinical safety data

A. Mutagenicity:

Cyclizine was not mutagenic in a full Ames test, including use of S9-microsomes but can nitrosate in vitro to form mutagenic products.

B. Carcinogenicity:

No long term studies have been conducted in animals to determine whether cyclizine has a potential for carcinogenesis. However, long-term studies with cyclizine administered with nitrate have indicated no carcinogenicity.

C. Teratogenicity:

Some animal studies are interpreted as indicating that cyclizine may be teratogenic at dose levels up to 25 times the clinical dose level. In another study, cyclizine was negative at oral dose levels up to 65 mg/kg in rats and 75 mg/kg in rabbits. The relevance of these studies to the human situation is not known.

D. Fertility:

In a study involving prolonged administration of cyclizine to male and female rats there was no evidence of impaired fertility after continuous treatment for 90-100 days at dose levels of approximately 15 and 25 mg/kg/day. There is no experience of the effect of Cyclizine Hydrochloride Tablets on human fertility.

6. Pharmaceutical particulars
6.1 List of excipients


Potato starch


Magnesium stearate

6.2 Incompatibilities

Not applicable

6.3 Shelf life

5 years

6.4 Special precautions for storage

Store below 25° C.

6.5 Nature and contents of container

Amber glass or polyethylene bottles with polyethylene tamper evident caps for pack size 100 tablets.

6.6 Special precautions for disposal and other handling

No special requirements

7. Marketing authorisation holder

Amdipharm UK Limited

Dashwood House,

69 Old Broad Street, London,

EC2M 1QS, United Kingdom

8. Marketing authorisation number(s)

PL 20072/0241

9. Date of first authorisation/renewal of the authorisation

01/1/2001 / 05/12/2005

10. Date of revision of the text


Company image
Dashwood House, 69 Old Broad Street, London, EC2M 1QS, UK
+44 (0)208 588 9131
Medical Information Direct Line
+44 (0)208 588 9131
Medical Information e-mail
[email protected]
Customer Care direct line
+44 (0)208 588 9273